Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Predictive biomarkers to guide therapy for cancer patients are a cornerstone of precision medicine. Discussed herein are considerations regarding the design and interpretation of such predictive biomarker studies. These considerations are important for both planning and interpreting prospective studies and for using specimens collected from completed randomized clinical trials. Specific issues addressed are differentiation between qualitative and quantitative predictive effects, challenges due to sample size requirements for predictive biomarker assessment, and consideration of additional factors relevant to clinical utility assessment, such as toxicity and cost of new therapies as well as costs and potential morbidities associated with routine use of biomarker-based tests.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Cited by
Deep Learning: Methods and Applications
Deng, L., & Yu, D. (2014) · Foundations and Trends® in Signal Processing · doi:10.1561/2000000039 · Cited by 3,480
Machine Learning Applications in Cancer Prognosis and Prediction
Kourou, K., Exarchos, T. P., Exarchos, K. P., Karamouzis, M. V., & Fotiadis, D. I. (2015) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2014.11.005 · Cited by 3,338
“In these studies prognostic and predictive features are considered which may be independent of a certain treatment or are integrated in order to guide therapy for cancer patients, respectively [2].”
BackgroundImaging biomarker roadmap for cancer studies
O'Connor, J. P. B., Aboagye, E. O., Adams, J. E., Aerts, H. J. W. L., Barrington, S. F., Beer, A. J., Boellaard, R., Bohndiek, S. E., Brady, M., Brown, G., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.162 · Cited by 1,091
Self-citationHarris, L. N., Ismaila, N., McShane, L. M., Andre, F., Collyar, D. E., Gonzalez-Angulo, A. M., Hammond, E. H., Kuderer, N. M., Liu, M. C., Mennel, R. G., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.2289 · Cited by 811
Self-citationBiomarker development in the precision medicine era: lung cancer as a case study
Vargas, A. J., & Harris, C. C. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.56 · Cited by 556
Metadata
- Authors
- Polley, M.-Y. C., Freidlin, B., Korn, E. L., Conley, B. A., Abrams, J. S., & McShane, L. M.
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2013-10-17
- Volume
- 105
- Issue
- 22
- Pages
- 1677-1683
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2167645795
- Cited by
- 150
- References
- 1
- FWCI
- 11.47
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. https://app.cochat.ai/papers/10.1093/jnci/djt282
- The paper
- Polley, M.-Y. C., Freidlin, B., Korn, E. L., Conley, B. A., Abrams, J. S., & McShane, L. M. (2013). Statistical and Practical Considerations for Clinical Evaluation of Predictive Biomarkers. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djt282
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.